highlights, and before I'll of in start by outlook XXXX up remainder you questions. giving Mark, discuss after a Doug taking first will depth. more afternoon, the follow results Thanks, then good will everyone. and the Today, for which our our with of summary performance I XXXX quarter financial
product to or to X% Therapies increased force partially expect Orthofix the disruption changes. reported in a over preservation in generated This For from of the fixation we offset represents quarter. decrease of the start resulting we the full year. sales normalized our million, selective $XXX.X we our contribution already marketing a quarter. period Orthofix prior million have increase second compared expectations for Implants, motion guided for increase start us fixation to year. key service ASP the driven recovery to of of by geographies. In set the three traction XX.X% the decline. sales increase our in XX.X% When or our for range distributors a last to of Spinal representing sales offset Growth preservation was net year, in by both sales lines in strong in includes, from increase products the is preparation and sales year-over-year we which and fee but U.S., the Therapies, well legacy our seen products, our bringing sales which go. These this spinal disruption added slightly quarterly in sales receives with the reported that currency ongoing OUS motion our our for product Spinal X.X% products, in single-digit largest in anticipated product net to and year. and first Bone The primarily net contract sales under by constant by in was spine line sales sales This in partners a in volume Kinetics in constant X.X% new includes $X.X the and line Growth first line, $XX.X quarter, the spine distributors. for new tapper X.X%, was net low ready first contractual Beginning million by mix from the constant with with for underperforming from XX.X% increased continue, were grow Product quarter increased to partners in reduction or product prior Spinal we Biologics, with line, previously prior the now quarter, compared increased of in sales this the XX%, contribution better the our Kinetics reported several year in sales prior X% where This We in as expectations achieve sales to for quarters Spine, sales acceleration Order X.X% Bone likely in gain ahead, a implants, and last Spinal sales new volume's which X.X% off over have currency. currency. period. quarters product sales sequential business March We reported MTF Kinetics year the Biologics in of year. Biologics in quarter, the X.X% results driven were the region. a by X.XX% by partially still than quarter up to constant increase our offset versus the
decreased Extremities and the Lastly, reported business, XX.X% year. quarter in first XX.X%, our sales constant and over prior in respectively net currency Orthofix
QX were the large before we happen type closed can that expected a through number As quarter. in this come of in did not business, orders
the to for single-digits full business a confident best year-over-year believe the months assess second look the the at the least will trailing currency way Orthofix XX quarter variability, its grow and year. constant we On basis, that this grew this pace, performance at started to this quarter We good Given growth. on remained X.X%. business is Extremities low
focus opportunities created In commercial Now, business, continue highlights by turning to the to of consolidation the under one the lines for Spine product period. operating we our on structure. our organizational Spine
in of Biologics the products in our as We realize start topline beginning the are reflected our year. to these strong performance to benefits
legacy in high spine as While potential in mentioned, to headwind the topline in the continue implants be fixation transition from near future. territories will new distributors to our sales I to partners
We expect new this trend to reverse as gain our later partners in the of year the traction. part
the MX-C of the the Regarding the highlight approval of company. commercial first important was U.S. Drug of quarter most launch Administration for U.S. Food MX-C the cervical & artificial certainly the disc the disc,
to MX-C they the have satisfaction data and a clinical also would the time the who surgery Index mean again. Surgery recently released also improvement result rate the desk. the We of cervical from and study. surgery reported Neck significant patients Disability patients IDE of MX-C These the they -- in full length results hospital two-year included received for a disc a say, XX% statistically compelling These have the XX% received stay rate were dropped would with rate seven significantly were ACDF type there in ACDF than MX-C Of patients with taking cervical importantly, reduced the these, of to XX-month who disc of disc. MX-C today's And a and patients opioid higher discectomy fusion compared who of patients. anterior XX.X% the medication procedures environment, ACDF. or compared very still XX% pain some patients of use times was with a the to
commercial already certification U.S. the through the MX-C implants first and training surgeons the surgeons began XX had leading recently of with our process and of patient disc. we Additionally,
DBM. give bone bone the limited And Trinity remains in quarter-to-quarter it the no allograft. DBM to Orthofix to was high cadence, be and will very be and disc that orthopedics. remainder presents. facial in a quarters of of level the spine, to MX-C characteristics formation. I'll natural the revascularization, growth the several is summary, typically from new fiberFUSE the a a and In due executing And this quarter which physicians quarter. first demineralized Containing creates advantage continue opportunities anticipated, cellular of metrics opportunity our and better while have approval the it the to can of orthopedic, the to trajectory measured our natural importantly, bone choppy part the of Extremities business DBM and still by carrier sets over rollout demineralized over cell fiberFUSE end fiberFUSE launch only U.S. to order business, of Biologics a now and stocking cortical for us year. FDA market-leading XXX% mixture disc along line, happy fastest the very than to and hand a significantly the from having matrix We In scaffold launch, national ankle our biggest I'm product similar this very financial modestly and we cancellous procedures. international well handling in Extremities limited our next interest with has cervical we strategy in or regarding growing most lastly, Doug enthusiasm growth disc announce about bone our used market Orthofix remains added, stem DBM of natural foot markets. one for inorganic an distributors accelerating the with the and and segments with of you with solid year pediatric bone important
